The Pharma Data

MAY 26, 2023

The expansion forms part of Catalent’s ongoing global strategy to increase its ability to handle, store and manage advanced therapies for clinical supply, and follows investments at its facilities in Philadelphia, Singapore, and Shanghai, China, in specialized, ultra-low temperature storage capabilities. With sites in the U.S.,

Clinical Supply 52

Clinical Supply Gene Therapy Gene Development 52

Pharmaceutical Technology

JUNE 2, 2023

Rentschler Biopharma has collaborated with Ikarovec for expediting the new gene therapies to treat ophthalmic disease. Under the deal, Rentschler Biopharma’s ATMP facility in Stevenage, UK, will undertake the bioprocess development of adeno-associated virus (AAV) material.

Gene Therapy 130

Gene Therapy Gene Clinical Supply Manufacturing 130

Pharmaceutical Technology

JUNE 19, 2023

Although only a small number of gene therapies have reached the market thus far, the industry is poised to grow quickly over the next few years. According to GlobalData’s clinical trials database, there are currently 1,231 planned and ongoing trials for gene therapies and gene-modified cell therapies alone.

Gene Therapy 130

Gene Therapy Gene Packaging Packaging 130

BioPharma Reporter

APRIL 27, 2021

Contract development and manufacturing organization, Catalent, has invested in the capabilities at its clinical supply services facility in Philadelphia, in the US, to further support biotech firms developing cell and gene therapies.

Gene Therapy 52

Gene Therapy Clinical Supply Gene Manufacturing 52

The Pharma Data

JUNE 7, 2023

Originally launched in 2019 for early-phase protein therapy development, OneBio Suite offers customers an integrated service to accelerate programs from development to manufacturing, including fill/finish and packaging, and support for clinical supply and commercial launch. at the BioProcess International Theater.

Manufacturing 40

Manufacturing Development Protein Gene Therapy 40

The Pharma Data

AUGUST 4, 2020

. UK-based Oxford Biomedica has signed a new development, manufacture and license agreement with Beam Therapeutics for next-generation CAR-T therapeutics. The agreement also puts in place a three year clinical supply agreement for the two companies.

Gene Editing 52

Gene Editing Licensing Licensing Clinical Supply 52

pharmaphorum

NOVEMBER 2, 2022

billion on offer in milestones if the programmes meet development and commercial objectives. According to a statement from the two companies, Arcturus will contribute its STARR self-amplifying mRNA vaccine and LUNAR lipid nanoparticle delivery platform, which has already been deployed in the development of COVID-19 vaccine ARCT-154.

Vaccination 52

Vaccination Vaccine Immune Response Gene Therapy 52